Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice

Journal of the National Cancer Institute

Volumn 88, Issue 7, 1996, Pages 419-429

  Leoneti, Carlo ^a   D'Agnano, Igea ^b   Lozupone, Francesco ^a   Valentini, Alessandra ^a   Geiser, Tim ^c   Zon, Gerald ^c   Calabretta, Bruno ^d,e   Citro, Gennaro ^a   Zupi, Gabriella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Institute of Biomedical Technologies   (Italy)

^c ILLUMINA INC   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; MALE; MELANOMA CELL; MOUSE; NONHUMAN; ONCOGENE C MYC;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; DRUG ADMINISTRATION SCHEDULE; FLOW CYTOMETRY; GENES, MYC; HUMANS; MELANOMA; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; THIONUCLEOTIDES; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0029873193     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.7.419     Document Type: Article

References (51)

1. Vogelstein B, Kinzler KW. The mullistep nature of cancer. Trends Genet 1993;9:138-41.
2. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993;261:1004-12.
3. Calabretta B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res 1991;51:4505-10.
4. Cohen JS. Oligonucleotides as therapeutic agents. Pharmacol Ther 1991; 52:211-25.
5. Eder PS, Devine RJ, Dagle JM, Walder JA. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res Dev 1991;1:141-51.
6. Dagle JM, Weeks DL, Walder JA. Pathways of degradation and mechanism of action of antisense in Xenopus laevis embryos. Antisense Res Dev 1991;1:11-20.
7. Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods 1987;13:97-102.
8. Stein CA, Subasinghe C, Shinozuka K, Cohen JS. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 1988; 16:3209-21.
9. Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleolide phosphorothioates in mice. Proc Natl Acad Sci U S A 1991;88:7595-9.
10. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67-70.
11. Biro S, Fu YM, Yu ZX, Epstein SE. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci U S A 1993;90:654-8.
12. Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A 1992;88:11823-7.
13. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, et al. Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A 1994;91:4504-8.
14. Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, et al. Biologic and therapeutic significance of MYB expression in human melanoma. Proc Natl Acad Sci U S A 1994;91:4499-503.
15. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, et al. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci U S A 1993;90:9901-5.
16. Costa A, Silvestrini R, Grignolio E, Clemente C, Attili A, Testori A. Cell kinetics as a prognostic tool in patients with metastatic malignant melanoma of the skin. Cancer 1987;60:2797-800.
17. Muhonen T, Pyrhonen S, Laasonen A, Wasenius VM, Asko-Setjavaara S, Franssila K, et al. Tumour growth rate and DNA flow cytometry parameters as prognostic factors in metastatic melanoma. Br J Cancer 1992;66:528-32.
18. Karlsson M, Boeryd B, Carstensen J, Kagedal B, Bratel AT, Wingren S. DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease. Br J Cancer 1993;67:134-8.
19. Meichle A, Philipp A, Eilers M. The function of Myc proteins. Biochim Biophys Acta 1992;1114:129-46.
20. Wickstrom EL, Bacon TA, Gonzales A, Freeman DL, Lyman GH, Wickstrom E. Human promyelocytic leukemia HL-60 cell proliferation and c-myc expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci U S A 1988;85:1028-32,
21. Holt JT, Redner RL, Nienhuis AW. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol 1988;8:963-73.
22. Harel-Bellan A, Ferris DK, Vinocour M, Holt JT, Farrar WL. Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxy-oligonucleotide in human T lymphocytes. J Immunol 1988;140:2431-5.
23. Versteeg R, Noordermeer IA, Kruse-Wolters KM, Ruiter DJ, Schrier PI. c-myc downregulates class I HLA expression in human melanomas. EMBO J 1988;7:1023-9.
24. Peltenburg LT, Schier PI. Transcriptional suppression of HLA-B expression by c-myc is mediated through the core promoter elements. Immunogenetics 1994;40:54-61.
25. van Elsas A, van Deursen E, Wielders R, van den Berg-Bakker CA, Schrier PI. ras oncogene activation does not induce sensitivity to natural killer cell-mediated cytolysis in human melanoma. J Invest Dermatol 1994; 103:117S-121S.
26. Greco C, Zupi G. Biological features and in vitro chemosensitivity of a new model of human melanoma. Anticancer Res 1987;7:839-44.
27. Zupi G, Mauro F, Balduzzi MA, Pardini MC, Cavaliere R, Greco C. Established melanoma cell lines from different metastatic nodules of a single patient. A useful model for cancer therapy. Proc Am Assoc Cancer Res 1985;26:22.
28. Clark WH Jr, Ainsworth AM, Bernardino EA, Yang CH, Mihm CM Jr, Reed RJ. The developmental biology of primary human malignant melanomas. Semin Oncol 1975;2:83-103.
29. Mottolese M, Venturo I, Benevolo M, Di Filippo F, Lopez M, Bigotti A, et al. Immunocytochemical diagnosis of amelanotic metastatic melanoma using monoclonal antibodies HMB-45 and Epl-3. Melanoma Res 1994;4: 53-8.
30. Greco C, Corsi A, Caputo M, Cavallari A, Calabresi F. Cyclophosphamide and iphosphamide against Lewis lung carcinoma: evaluation of toxic and therapeutic effects. Tumori 1979;65:169-80.
31. Chomczynsky P, Sacchi N. Single step method of RNA isolation by acidic guanidium thiocyanate phenol extraction. Anal Biochem 1987;162:156-9.
32. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132:6.
33. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory, 1989.
34. Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell 1987;49:161-70.
35. Dugaiczyk A, Haron JA, Stone EM, Dennison OE, Rothblum KN, Schwartz RJ. Cloning and sequencing of a deoxyribonucleic acid copy of glyceraldehyde-3-phosphate dehydrogenase messenger ribonucleic acid isolated from chicken muscle. Biochemistry 1983;22:1605-13.
36. Geran RI, Greenberg NH, Macdonald MM, Shumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. 3rd ed. Cancer Chemother Rep 1972;3:1-88.
37. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:681-5.
38. Evan GI, Lewis GK, Ramsay G, Bishop JM. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 1985;5:3610-6.
39. Chenevix-Trench G, Martin NG, Ellem KA. Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc, and p53. Oncogene 1990;5:1187-93.
40. Yaswen P, Stampfer MR, Ghosh K, Cohen JS. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 1993;3:67-77.
41. Kimura S, Maekawa T, Hirakawa K, Murakami A, Abe T. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL 60 cells. Cancer Res 1995;55:1379-84.
42. Branda RF, Moore AL, Mathews L, McCormack JJ, Zon G. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-I. Biochem Pharmacol 1993;45:2037-43.
43. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-9.
44. Mojcik CF, Gourley MF, Klinman DM, Krieg AM, Gmelig-Meyling F, Steinberg AD, et al. Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. Clin Immunol Immunopathol 1993; 67:130-6.
45. Skorski T, Nieborowska-Skorska M, Campbell K, lozzo RV, Zon G, Darzynkiewicz Z, et al. Leukemia treatment in SCID mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J Exp Med 1995; 182:1645-53.
46. Milner AE, Grand RJ, Waters CM, Gregory CD. Apoptosis in Burkitt lymphoma cells is driven by c-myc. Oncogene 1993;8:3385-91.
47. Yuh YS, Thompson EB. Glucocorticoid effect on oncogene/growth gene expression in human T lymphoblastic leukemic cell line CCRF-CEM. Specific c-myc mRNA suppression by dexamethasone. J Biol Chem 1989; 264:10904-10.
48. Nazareth LV, Harbour DV, Thompson EB. Mapping the human glucocorticoid receptor for leukemic cell death. J Biol Chem 1991;266:12976-80.
49. Thulasi R, Harbour DV, Thompson EB. Suppression of c-myc is a critical step in glucocorticoid-induced human leukemic cell lysis. J Biol Chem 1993;268:18306-12.
50. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.
51. Wood AC, Waters CM, Garner A, Hickman JA. Changes in c-myc expression and the kinetics of dexamethasone-induced programmed cell death (apoptosis) in human lymphoid leukaemia cells. Br J Cancer 1994;69:663-9.